DHL Group has announced a strategic investment of EUR 2 billion over the next five years to enhance its logistics capabilities in the Life Sciences & Healthcare (LSH) sector. Of this, EUR 500 million is specifically allocated to the Asia Pacific region. This investment addresses the region’s increasing spending power, growing middle class, and rapidly aging population, all of which have spurred innovation and investment in healthcare.
This significant commitment reinforces DHL’s dedication to supporting healthcare customers in their growth, innovation, and ability to serve patients more effectively worldwide. The EUR 2 billion global investment is strategically distributed, with 50% allocated to the Americas, 25% to Asia Pacific, and 25% to the EMEA region. This expansion aims to deliver integrated, faster, more reliable, and patient-centric logistics solutions globally.
The investment will focus on upgrading high-quality infrastructure and technology across all logistics touchpoints, including storage, order fulfillment, distribution, global shipping, and last-mile delivery. This will create more resilient, scalable, and responsive supply chains for customers. A substantial portion of the investment will be directed towards establishing new cross-divisional Good Distribution Practice (GDP)-certified Pharma Hubs for multi-temperature shipments, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions for sustainable delivery.
As demand grows in critical areas such as clinical trials, biopharma, and cell and gene therapies, DHL is also investing in specialized cooling infrastructure to accommodate low and ultra-low temperature ranges. Furthermore, the Group will implement cutting-edge IT systems to provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.
DHL Group is consolidating its life sciences and healthcare expertise under a new unified brand, DHL Health Logistics. This new brand aims to create a seamless, end-to-end experience for customers, simplifying the management of complex, cross-border supply chains with confidence, agility, and high-quality service. This approach is designed to meet the needs of pharmaceutical, biopharma, and medical customers who require agile, connected logistics solutions beyond traditional service lines.
“Similar to DHL Group’s purpose of ‘Connecting people, improving lives,’ our strategic investment in Life Sciences & Healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”
In 2024, DHL Group generated over EUR 5 billion in global revenue from life sciences and healthcare logistics. With an additional EUR 5 billion in projected incremental revenue by 2030, DHL Group is scaling its operations to match the fast-evolving needs of the industry and its end-users – healthcare professionals and patients alike.
Through this strategic investment, DHL Group is reinforcing its commitment to the Life Science and Healthcare sector and demonstrating a profound dedication to patient care. The company aims to ensure the efficient and reliable delivery of essential pharmaceutical products, clinical trials, and cell & gene therapies. This approach positions DHL Group at the forefront of the industry, fully equipped to tackle challenges and seize opportunities in a rapidly transforming market.
Currently, DHL Group operates nearly 600 sites, hubs, and warehouses across close to 130 countries dedicated to Life Sciences & Healthcare logistics, encompassing more than 2.5 million square meters of temperature-controlled warehouse space. In Asia Pacific, DHL has over 300,000 square meters of fully compliant warehousing space in 15 countries, with new facilities to be announced in Singapore, Malaysia, and Korea.
In addition to infrastructure investments, DHL Group recently acquired CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies, further strengthening its capabilities in this segment as part of its overall investment strategy.
อัพเดตข่าวสารและบทความที่น่าสนใจในอุตสาหกรรมโลจิสติกส์ก่อนใคร ผ่าน Line Official Account @Airfreight Logistics เพียงเพิ่มเราเป็นเพื่อน @Airfreight Logistics หรือคลิกที่นี่
